Recent advances in molecular gynaecological pathology

Histopathology

Volumn 55, Issue 3, 2009, Pages 243-249

  Herrington, C Simon ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

Cervix; Endometrium; Gynaecology; Molecular; Ovary; Pathology; Vulva

Indexed keywords

WART VIRUS VACCINE;

ANUS TUMOR; CARCINOGENESIS; CLINICAL PRACTICE; ENDOMETRIUM TUMOR; FEMALE; FEMALE GENITAL TRACT TUMOR; GENE MUTATION; GYNECOLOGIC CANCER; GYNECOLOGY; HUMAN; MOLECULAR GYNECOLOGICAL PATHOLOGY; OVARY TUMOR; PATHOLOGY; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX TUMOR; VACCINATION; VULVA TUMOR;

ALPHAPAPILLOMAVIRUS; CANCER VACCINES; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 69549138177     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2008.03216.x     Document Type: Review

References (59)

1. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999 189 12 19.
2. Bedell MA, Hudson JB, Golub TD, Turyk ME, Hosken M, Wilbanks GD. Amplification of human papillomavirus in vitro is dependent on epithelial differentiation. J. Virol. 1991 65 2254 2260.
3. Stanley MA. Genital human papillomavirus infections - current and prospective therapies. J. Natl Cancer Inst. 2003 31 117 124.
4. Wilson BG, West M, Woytek K, Rangasamy D. Papillomavirus E1 proteins: form, function and features. Virus Genes 2002 24 275 290.
5. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. 2006 110 525 541.
6. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007 369 1861 1868.
7. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007 356 1928 1943. (Pubitemid 46740303)
8. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004 364 1757 1765.
9. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006 367 1247 1255.
10. Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007 369 1693 1702.
11. Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007 369 2161 2170.
12. Sánchez IE, Dellarole M, Gaston K, de Prat Gay G. Comprehensive comparison of the interaction of the E2 master regulator with its cognate target DNA sites in 73 human papillomavirus types by sequence statistics. Nucleic Acids Res. 2008 36 756 769.
13. Gray L, Jolly C, Herrington CS. Human papillomaviruses and their effects on the cell cycle and apoptosis. In Nash AA, Randall RE eds. Molecular pathogenesis of virus infection. Reading : Society for General Microbiology, 2005 235 252.
14. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 2004 64 3878 3884.
15. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J. Pathol. 2007 212 356 367.
16. Hopman AH, Theelen W, Hommelberg PP et al. Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J. Pathol. 2006 210 412 419.
17. Muralidhar B, Goldstein LD, Ng G et al. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J. Pathol. 2007 212 368 377.
18. Wilting SM, Snijders PJ, Meijer GA et al. Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. J. Pathol. 2006 209 220 230.
19. Henken FE, Wilting SM, Overmeer RM et al. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br. J. Cancer 2007 97 1457 1464.
20. Klaes R, Benner A, Friedrich T et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am. J. Surg. Pathol. 2002 26 1389 1399.
21. Shi J, Liu H, Wilkerson M et al. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions. Hum. Pathol. 2007 38 1335 1344.
22. Badr RE, Walts AE, Chung F, Bose S. BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am. J. Surg. Pathol. 2008 32 899 906.
23. Pinto AP, Schlecht NF, Woo TY, Crum CP, Cibas ES. Biomarker (ProEx C, p16(INK4A), and MiB-1) distinction of high-grade squamous intraepithelial lesion from its mimics. Mod. Pathol. 2008 21 1067 1074.
24. Hart WR. Vulvar intraepithelial neoplasia: historical aspects and current status. Int. J. Gynecol. Pathol. 2001 20 16 30.
25. Skapa P, Zamecnik J, Hamsikova E et al. Human papillomavirus (HPV) profiles of vulvar lesions: possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination. Am. J. Surg. Pathol. 2007 31 1834 1843.
26. van der Avoort IA, Shirango H, Hoevenaars B et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. Int. J. Gynecol. Pathol. 2006 25 22 29.
27. van Seters M, ten Kate FJ, van Beurden M et al. In the absence of (early) invasive carcinoma, vulvar intraepithelial neoplasia associated with lichen sclerosus is mainly of undifferentiated type: new insights in histology and aetiology. J. Clin. Pathol. 2007 60 504 509.
28. Liegl B, Regauer S. p53 immunostaining in lichen sclerosus is related to ischaemic stress and is not a marker of differentiated vulvar intraepithelial neoplasia (d-VIN). Histopathology 2006 48 268 274.
29. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004 444 213 223.
30. Mutter GL, Zaino RJ, Baak JP, Bentley RC, Robboy SJ. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int. J. Gynecol. Pathol. 2007 26 103 114.
31. Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res. 2001 61 4311 4314.
32. Irving JA, Catasús L, Gallardo A et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum. Pathol. 2005 36 605 619.
33. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000 88 814 824.
34. Catasus L, Gallardo A, Cuatrecasas M, Prat J. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod. Pathol. 2008 21 131 139.
35. Modica I, Soslow RA, Black D, Tornos C, Kauff N, Shia J. Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am. J. Surg. Pathol. 2007 31 744 751.
36. Velasco A, Pallares J, Santacana M et al. Loss of heterozygosity in endometrial carcinoma. Int. J. Gynecol. Pathol. 2008 27 305 317.
37. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int. J. Gynecol. Pathol. 2004 23 200 205.
38. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int. J. Gynecol. Pathol. 2008 27 161 174.
39. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman R, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 2004 23 41 44.
40. Singer G, Oldt R, Cohen Y et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl Cancer Inst. 2003 95 484 486.
41. Singer G, Shih IeM, Truskinovsky A, Umudum H, Kurman R. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int. J. Gynecol. Pathol. 2003 22 37 41.
42. Singer G, Stöhr R, Cope L et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol. 2005 29 218 224.
43. Garrett AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS, Mok SC. k-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int. J. Gynecol. Pathol. 2001 20 244 251.
44. Yemelyanova AV, Vang R, Judson K, Wu LS, Ronnett BM. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am. J. Surg. Pathol. 2008 32 128 138.
45. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 2005 47 231 247.
46. Ji H, Isacson C, Seidman JD, Kurman R, Ronnett BM. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int. J. Gynecol. Pathol. 2002 21 391 400.
47. Oliva E, Sarrió D, Brachtel EF et al. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. J. Pathol. 2006 208 708 713.
48. Catasús L, Bussaglia E, Rodrguez I et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum. Pathol. 2004 35 1360 1368.
49. Wu R, Hendrix-Lucas N, Kuick R et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007 11 321 333.
50. Ali-Fehmi R, Khalifeh I, Bandyopadhyay S et al. Patterns of loss of heterozygosity at 10q23.3 and microsatellite instability in endometriosis, atypical endometriosis, and ovarian carcinoma arising in association with endometriosis. Int. J. Gynecol. Pathol. 2006 25 223 229.
51. Prowse AH, Manek S, Varma R et al. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int. J. Cancer 2006 119 556 562.
52. Sato N, Tsunoda H, Nishida M et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000 60 7052 7056.
53. Kurman R, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 2008 27 151 160.
54. Jarboe EA, Folkins AK, Drapkin R, Ince TA, Agoston ES, Crum CP. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2008 53 127 138.
55. Naora H. The heterogeneity of epithelial ovarian cancers: reconciling old and new paradigms. Expert Rev. Mol. Med. 2007 9 1 12.
56. Russell SE, McCluggage WG. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J. Pathol. 2004 203 617 619.
57. Lee YS, Miron A, Drapkin R et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 2007 211 26 35.
58. Jarboe E, Folkins A, Nucci MR et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int. J. Gynecol. Pathol. 2008 27 1 9.
59. Kindelberger DW, Lee YS, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 2007 31 161 169.